{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:35:32Z","timestamp":1792787732619,"version":"4.5.0"},"reference-count":67,"publisher":"SAGE Publications","issue":"10-11","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases","award":["UM1 AI120184"],"award-info":[{"award-number":["UM1 AI120184"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:p>\n                    Several forms of HIV pre-exposure prophylaxis (PrEP) are approved, prescribed off-label, or in development in the United States, including daily oral tablets, long-acting injectable cabotegravir (CAB-LA), removable implants, and rectal tenofovir products. To understand how health care providers prioritize among these options, 30 providers from the United States, Thailand, and South Africa completed online surveys, and 10 participated in in-depth interviews. Providers shared their perspectives on current and emerging PrEP products, key informational needs for gay and bisexual men, and preferred educational strategies. When asked to rank PrEP options if all were simultaneously available, providers most often prioritized removable implants (\n                    <jats:italic toggle=\"yes\">N<\/jats:italic>\n                    = 3), daily oral PrEP (\n                    <jats:italic toggle=\"yes\">N<\/jats:italic>\n                    = 3), CAB-LA (\n                    <jats:italic toggle=\"yes\">N<\/jats:italic>\n                    = 1), and rectal douches\/enemas (\n                    <jats:italic toggle=\"yes\">N<\/jats:italic>\n                    = 1), while others (\n                    <jats:italic toggle=\"yes\">N<\/jats:italic>\n                    = 2) emphasized patient preference. Overall, providers noted that each product has unique advantages and expressed support for digital shared decision-making tools to enhance patient\u2013provider communication about PrEP selection.\n                  <\/jats:p>","DOI":"10.1177\/08892229261480775","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:30:41Z","timestamp":1787632241000},"page":"307-317","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Provider Preferences on Existing and Potential Future Biomedical HIV Prevention Products: A Qualitative Study in the United States, Thailand, and South Africa"],"prefix":"10.1177","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6303-3809","authenticated-orcid":false,"given":"Christine","family":"Tagliaferri Rael","sequence":"first","affiliation":[{"name":"College of Nursing, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doyel","family":"Das","sequence":"additional","affiliation":[{"name":"College of Nursing, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA."},{"name":"Columbia University Mailman School of Public Health, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Giguere","sequence":"additional","affiliation":[{"name":"College of Medicine, Florida State University, Tallahassee, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Porter","sequence":"additional","affiliation":[{"name":"College of Nursing, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA."},{"name":"Columbia University Mailman School of Public Health, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Bryndza Tfaily","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camagu","family":"Tuswa Haynes","sequence":"additional","affiliation":[{"name":"HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titcha","family":"Ho","sequence":"additional","affiliation":[{"name":"Department Of English, Baruch College, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"McKenna","sequence":"additional","affiliation":[{"name":"Consultant at Stacey McKenna Writes, Fort Collins, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Lopez-R\u00edos","sequence":"additional","affiliation":[{"name":"Community Health and Prevention, Drexel University Dornsife School of Public Health, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Lentz","sequence":"additional","affiliation":[{"name":"Temple University, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Dolezal","sequence":"additional","affiliation":[{"name":"HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Stonbraker","sequence":"additional","affiliation":[{"name":"College of Nursing, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Hendrix","sequence":"additional","affiliation":[{"name":"Temple University, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"D\u2019Aquila","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Hope","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"1.CDC. On-Demand PrEP Vol. 2023. CDC: Atlanta GA; 2022. Available from: https:\/\/www.cdc.gov\/hiv\/prevention\/prep.html?utm_source"},{"key":"e_1_3_3_3_1","unstructured":"2.CDC. HIV basics: PrEP Vol. 2016. Centers for Disease Control and Prevention: Atlanta GA; 2015. Available from: https:\/\/www.cdc.gov\/hiv\/prevention\/prep.html?utm_source"},{"key":"e_1_3_3_4_1","unstructured":"3.Viiv. Apretude Prescribing Information Vol. 2024. ViiV Healthcare: Research Triangle Park NC; 2022. Available from: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Apretude\/pdf\/APRETUDE-PI-PIL-IFU.PDF"},{"key":"e_1_3_3_5_1","unstructured":"4.Centers for Disease Control C.D.C. Clinicians\u2019 quick guide: What is injectable HIV PrEP. CDC: Atlanta GA; 2022. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/158767?utm_source"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.12.024"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02703-5"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000591"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2024-056209"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad535"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00405-2"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2023.0120"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-016-1565-9"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113849"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002670"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.2196\/16904"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2021.0075"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2018.05.030"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.161577"},{"key":"e_1_3_3_21_1","volume-title":"HIV Endgame: Closing Gaps in the Care Cascade","author":"McGowan I","year":"2016","unstructured":"20.McGowan I. What\u2019s in the biomedical prevention pipeline. in HIV Endgame: Closing Gaps in the Care Cascade (Toronto, Canada, 2016)."},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1227"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30238-3"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2019.1587352"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.01.051"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.9745\/GHSP-D-13-00010"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2022.0035"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2018.0214"},{"key":"e_1_3_3_29_1","unstructured":"28.CDC. CDC Factsheet: HIV Among Gay and Bisexual Men: February 2017. CDC: Atlanta GA; 2017. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/49807?utm_source"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228620"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87474-7"},{"key":"e_1_3_3_32_1","unstructured":"31.Qualtrics. Qualtrics. Qualtrics: Provo Utah; 2020. Available from: https:\/\/www.qualtrics.com\/?utm_source"},{"key":"e_1_3_3_33_1","unstructured":"32.Dedoose. Dedoose version 9.0.17 web application for managing analyzing and presenting qualitative and mixed methods research data. SocioCultural Research Consultants LLC: Los Angeles CA; 2021. Available from: https:\/\/www.dedoose.com\/release-features\/9-0?utm_source"},{"key":"e_1_3_3_34_1","unstructured":"33.Salda\u00f1a J. The coding manual for qualitative researchers: Second Edition Sage; London; 2013. Available from: https:\/\/collegepublishing.sagepub.com\/products\/the-coding-manual-for-qualitative-researchers-5-287917?utm_source"},{"key":"e_1_3_3_35_1","unstructured":"34.AIDS Vaccine Advocacy Coalition A.V.A.C. PrEPWatch: Country Data Vol. 2025. AIDS Vaccine Advocacy Coalition A.V.A.C: New York NY; 2025. Available from: https:\/\/www.prepwatch.org\/data-by-country\/"},{"key":"e_1_3_3_36_1","unstructured":"35.Johnson&Johnson. South Africa Health Products Regulatory Authority Approves Dapivirine Ring Developed by the International Partnership for Microbicides. Johnson&Johnson: New Brunswick NJ 2022. Available from: https:\/\/www.jnj.com\/media-center\/press-releases\/south-africa-health-products-regulatory-authority-approves-dapivirine-ring-developed-by-the-international-partnership-for-microbicides?utm_source"},{"issue":"6","key":"e_1_3_3_37_1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/jama.2025.10325","article-title":"FDA approves first twice-yearly PrEP for long-acting HIV prevention","volume":"334","author":"Anderer S","year":"2025","unstructured":"36.Anderer S. FDA approves first twice-yearly PrEP for long-acting HIV prevention. JAMA 2025;334(6):477.","journal-title":"JAMA"},{"key":"e_1_3_3_38_1","unstructured":"37.SAHPRA S.A.H.P.R.A. SAHPRA Registers Lenacapavir. SAHPRA Pretoria: South Africa; 2025. Available from: https:\/\/www.sahpra.org.za\/wp-content\/uploads\/2025\/10\/SAHPRA-Registers-Lenacapavir.jpg"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.9745\/GHSP-D-20-00229"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.4054\/DemRes.2022.46.4"},{"key":"e_1_3_3_41_1","unstructured":"40.Food and Drug Administration F.D.A. Birth Control: From the FDA Office of Women\u2019s Health Vol. 2025. U.S. Food and Drug Administration: Silver Spring MD; 2024. Available from: https:\/\/www.fda.gov\/consumers\/womens-health-topics\/birth-control?utm_source"},{"key":"e_1_3_3_42_1","first-page":"1403","article-title":"Long-lasting, injectable HIV prevention drug set for \u201caggressive\u201d roll-out in Africa","volume":"383","author":"Cohen J","year":"2024","unstructured":"41.Cohen J. Long-lasting, injectable HIV prevention drug set for \u201caggressive\u201d roll-out in Africa. Science (1979) 2024;383:1403.","journal-title":"Science (1979)"},{"issue":"1","key":"e_1_3_3_43_1","first-page":"131","article-title":"The norplant debate: Birth control or woman control","volume":"25","author":"Spitz SS","year":"1993","unstructured":"42.Spitz SS. The norplant debate: Birth control or woman control. Columbia Human Rights Law Rev 1993;25(1):131\u2013169.","journal-title":"Columbia Human Rights Law Rev"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1783\/147118910793048629"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.3109\/09513590.2011.652247"},{"key":"e_1_3_3_46_1","unstructured":"45.Nexplanon. Nexplanon (etonogestrel implant) 68mg Radiopaque. Nexplanon; 2025."},{"key":"e_1_3_3_47_1","unstructured":"46.Nexplanon. Nexplanon FAQs. 2025 Vol. 2025. Nexplanon FAQs. Available from: https:\/\/www.nexplanon.com\/?utm_source"},{"key":"e_1_3_3_48_1","unstructured":"47.Testopel. Testopel testosterone pellets. Testopel: United States. 2020 Vol. 2020. Available from: https:\/\/www.testopel.com\/treatment-and-administration"},{"key":"e_1_3_3_49_1","unstructured":"48.Myhealthalberta.ca. Implant for birth control: Care instructions Vol. 2024. My Health Alberta: Alberta Canada; 2024. Available from: https:\/\/myhealth.alberta.ca\/Health\/aftercareinformation\/pages\/conditions.aspx?hwid=ug6410"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2016.1146653"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30089-9"},{"key":"e_1_3_3_52_1","unstructured":"51.Giguere R et al. The potential for a rectal microbicide douche: Findings from an international survey. In: CROI. CROI: Boston MA; 2020."},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-018-2336-6"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-020-00535-w"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2021.0066"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/13691058.2021.1909142"},{"key":"e_1_3_3_57_1","unstructured":"56.Porter J et al. The addition of long-acting injectable cabotegravir (CAB-LA) as HIV pre-exposure prophylaxis (PrEP) for transgender women: Perspectives of healthcare providers. In: American Public Health Association Annual Meeting. American Public Health Association Annual Meeting: Boston MA; 2022."},{"key":"e_1_3_3_58_1","unstructured":"57.Altice F. Implementation of PrEP in vulnerable populations. In: Bio-behavioral symposium: Moving the frontiers of PrEP research forward on axes of biology implementation science and behavior. Bio-behavioral symposium: Moving the frontiers of PrEP research forward on axes of biology implementation science and behavior: New York NY; 2022."},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-020-1065-8"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/16549716.2017.1332259"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.2196\/14230"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.2196\/21839"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.2196\/15888"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-12015-w"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26497"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1177\/23259582261471981"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/JNC.0000000000000642"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08892229261480775","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08892229261480775","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08892229261480775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:20:01Z","timestamp":1789888801000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08892229261480775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":67,"journal-issue":{"issue":"10-11","published-print":{"date-parts":[[2026,11,1]]}},"alternative-id":["10.1177\/08892229261480775"],"URL":"https:\/\/doi.org\/10.1177\/08892229261480775","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}